Know Cancer

or
forgot password

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer


N/A
N/A
N/A
Not Enrolling
Female
Cervical Cancer, Cervix

Thank you

Trial Information

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer


This study is done to gather preliminary data for determining the best way to test EGFR
expression in patients with cervical cancer who will receive treatment with EGFR inhibitors
in the future.

This study is designed to obtain preliminary data of genomic and phenotypic alterations of
the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive
cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic
(over-expression, amplification, point mutations, etc.) and phenotypic alterations of other
transduction pathways interacting with the EGFR pathway.


Inclusion Criteria:



- Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up
of at least 24 months, existing at the Department of Pathology will be retrieved by
the Tissue Repository, de-identified them and provided with code numbers that will
not be linked to patient's data.

Exclusion Criteria:

- None Specified.

Type of Study:

Interventional

Study Design:

N/A

Principal Investigator

Claire Verschraegen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of New Mexico

Authority:

United States: Institutional Review Board

Study ID:

INST 0548C

NCT ID:

NCT00298064

Start Date:

December 2005

Completion Date:

February 2008

Related Keywords:

  • Cervical Cancer
  • Cervix
  • Cervical cancer
  • EGFR
  • cervical
  • genomic
  • DNA
  • markers
  • prognostic
  • gene
  • epidermal growth factor
  • Uterine Cervical Neoplasms

Name

Location

University of New Mexico Albuquerque, New Mexico  87131